Ann: Quarterly Update and Appendix 4C, page-58

As much as a meaningful $$ qtly report would be great, more bullish to me would be a UK or European Telehealth contract, and/or a rethink by the FDA. There is also so much left field potential that could drop at any time that would dwarf the quarterly.
This company is disruptive. It has the ONLY respiratory solution in the world of Telehealth. Whether a market rerate happens in October as a result of a strong quarterly, or in the next couple of quarters, it will happen. You don’t fluke the high % clinical diagnostic numbers, you earn them through the brilliant foresight of Professor Abeyratne.